Skip navigation
  •  Home
  • UDC 
    • Getting started
    • RUC Policies
    • FAQ
    • FAQ on Copyright
    • More information at INFOguias UDC
  • Browse 
    • Communities
    • Browse by:
    • Issue Date
    • Author
    • Title
    • Subject
  • Help
    • español
    • Gallegan
    • English
  • Login
  •  English 
    • Español
    • Galego
    • English
  
View Item 
  •   DSpace Home
  • 1. Investigación
  • Instituto de Investigación Biomédica da Coruña (INIBIC)
  • Insuficiencia cardiaca avanzada e transplante cardiaco
  • INIBIC-ICATC - Artigos
  • View Item
  •   DSpace Home
  • 1. Investigación
  • Instituto de Investigación Biomédica da Coruña (INIBIC)
  • Insuficiencia cardiaca avanzada e transplante cardiaco
  • INIBIC-ICATC - Artigos
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Beta-blocker exposure and survival in patients with transthyretin amyloid cardiomyopathy

Thumbnail
View/Open
BargeC_BetaB.pdf (360.7Kb)
Use this link to cite
http://hdl.handle.net/2183/32195
Collections
  • INIBIC-ICATC - Artigos [143]
Metadata
Show full item record
Title
Beta-blocker exposure and survival in patients with transthyretin amyloid cardiomyopathy
Author(s)
Barge-Caballero, Gonzalo
Barge-Caballero, Eduardo
López-Pérez, Manuel
Bilbao-Quesada, Raquel
González-Babarro, Eva
Gómez-Otero, Inés
López-López, Andrea
Gutiérrez-Feijoo, Mario
Varela-Román, Alfonso
González-Juanatey, Carlos
Díaz-Castro, Óscar
Crespo-Leiro, María Generosa
Date
2022-02
Citation
Barge-Caballero G, Barge-Caballero E, López-Pérez M, Bilbao-Quesada R, González-Babarro E, Gómez-Otero I, López-López A, Gutiérrez-Feijoo M, Varela-Román A, González-Juanatey C, Díaz-Castro Ó, Crespo-Leiro MG. Beta-blocker exposure and survival in patients with transthyretin amyloid cardiomyopathy. Mayo Clin Proc. 2022 Feb;97(2):261-273.
Abstract
[Abstract] Objective: To investigate a potential association between beta-blocker exposure and survival in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Methods: In this real-world prospective registry of 128 consecutive patients with ATTR-CM recruited in 7 institutions in Galicia (Spain), survival of 65 patients who received beta blockers on registry enrollment was compared with that of 63 untreated controls by means of both unweighted Cox regression and Cox regression with inverse probability of treatment weighting. Tolerance to and adverse effects of beta blockers were recorded. Median study follow-up was 520 days. Results: Patients with ATTR-CM who received beta blockers showed statistically significant lower all-cause mortality than untreated controls as evaluated by either unweighted Cox regression (hazard ratio, 0.31; 95% CI, 0.12 to 0.79) or Cox regression with inverse probability of treatment weighting (hazard ratio, 0.18; 95% CI, 0.08 to 0.41; P<.001). Several sensitivity analyses confirmed the internal validity of these results. The overall frequency of beta-blocker suspension due to adverse effects was 25% (95% CI, 15.5% to 34.5%). Conclusion: In this real-world, prospective, multi-institutional registry, patients with ATTR-CM who received beta blockers had lower all-cause mortality than untreated controls.
Keywords
Adrenergic beta-antagonists
Amyloid neuropathies, Familial
Quality of life
 
Editor version
https://doi.org/10.1016/j.mayocp.2021.08.006
ISSN
0025-6196

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

My Account

LoginRegister

Statistics

View Usage Statistics
Sherpa
OpenArchives
OAIster
Scholar Google
UNIVERSIDADE DA CORUÑA. Servizo de Biblioteca.    DSpace Software Copyright © 2002-2013 Duraspace - Send Feedback